Sensorion Will Present at the Bioprocessing Summit Europe Conference on March 22, 2022 in Barcelona
MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation in person of Sensorion’s management in the Bioprocessing Summit Europe, held in person and virtually on March 22-24, 2022 in Barcelona, Spain.
Christine Le Bec, Head of CMC Gene Therapy, will chair a session entitled “Navigating Gene Therapy CMC and Analytics” at 2.25 am - 6.00 am EDT (8.25 am - 12 am CET) on Tuesday, March 22nd.
Otmane Boussif, Chief Technical Officer, will chair a session entitled “Gene Therapy Analytics” at 7.30 am -11.15 am EDT (1.30 pm - 5.15 pm CET), on Tuesday, March 22nd where Christine Le Bec will give a talk, in person, the same day, on the “Characterization of Dual AAV Vector Otoferlin” at 8.05 am - 8.35 am EDT (2.05 pm - 2.35 pm CET).
Otmane Boussif will also facilitate an in-person interactive discussion entitled “Gene Therapy CMC and Development” at 11.15 am - 12 am EDT (5.15 pm - 6 pm CET) the same day.
The agenda of the conference can be found here.
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates, and has a pipeline of small molecule and gene therapy-based programs.
Sensorion is assessing next steps to advance clinical development of SENS-401 for SSNHL and for cisplatin-induced ototoxicity (CIO). Sensorion is advancing, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation.
Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has gene therapy programs aimed at correcting hereditary monogenic forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, Usher Syndrome Type 1 related deafness and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.
This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2020 annual financial report published on April 9, 2021, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005917/en/
View this news release online at: